Anti-Fibrinolytic Drugs - Israel | Statista Market Forecast

The Anti-Fibrinolytic Drugs market in Israel is expected to generate a revenue of US$49.31m in 2024.
It is projected to exhibit a compound annual growth rate (CAGR 2024-2029) of 4.73%, leading to a market volume of US$62.14m by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$9.86bn in 2024.
Israel is experiencing a surge in the demand for anti-fibrinolytic drugs, driven by the country's advanced healthcare system and high prevalence of cardiovascular diseases.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Anti-Fibrinolytic Drugs are used to prevent the breakdown of blood clots in the body. In Israel, the market for these drugs has been developing in a certain way due to various factors.

Customer preferences: Israeli customers prefer drugs that are effective and have minimal side effects. They are willing to pay a premium price for drugs that meet these criteria. They also prefer drugs that are easily accessible and can be obtained without much hassle.

Trends in the market: The Anti-Fibrinolytic Drugs market in Israel has been growing steadily due to an increase in the prevalence of bleeding disorders. This has led to an increase in the demand for drugs that can prevent excessive bleeding. Another trend in the market is the development of new drugs that are more effective and have fewer side effects. These drugs are expected to drive the growth of the market in the coming years.

Local special circumstances: Israel has a well-developed healthcare system that provides universal coverage to its citizens. This has led to an increase in the demand for Anti-Fibrinolytic Drugs as more people have access to healthcare. Additionally, Israel has a high incidence of bleeding disorders such as hemophilia, which has further increased the demand for these drugs.

Underlying macroeconomic factors: Israel has a strong economy with a high GDP per capita. This has led to an increase in the purchasing power of its citizens, making it easier for them to afford expensive drugs. Additionally, Israel has a well-developed pharmaceutical industry that has been investing heavily in research and development. This has led to the development of new drugs that are more effective and have fewer side effects, further driving the growth of the Anti-Fibrinolytic Drugs market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.